Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marine Gilabert

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 13, 2019
International Study Group of Pancreatic Surgery type 3 and 4 venous resections in patients with pancreatic adenocarcinoma:the Paoli-Calmettes Institute experienceAbdallah Al Faraï, Jonathan Garnier, Jacques Ewald, et al.
World Journal of Surgical Oncology|June 6, 2019
Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinomaPauline Duconseil, Jonathan Garnier, Victoria Weets, et al.
Anti-Cancer Drugs|September 11, 2009
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 statusAnthony Gonçalves, Mathilde Deblock, Benjamin Esterni, et al.
BMC Medicine|September 21, 2017
A 25-gene classifier predicts overall survival in resectable pancreatic cancerDavid J Birnbaum, Pascal Finetti, Alexia Lopresti, et al.
JCI Insight|June 14, 2019
Sensitive and easy screening for circulating tumor cells by flow cytometryAlexia Lopresti, Fabrice Malergue, François Bertucci, et al.
Oncotarget|September 3, 2016
Prognostic value of PDL1 expression in pancreatic cancerDavid J Birnbaum, Pascal Finetti, Alexia Lopresti, et al.
Journal of Cellular Physiology|March 6, 2013
Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugsMarine Gilabert, Maria Inés Vaccaro, Martin E Fernandez-Zapico, et al.
British Journal of Cancer|January 30, 2022
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO studySonia Zaibet, Vincent Hautefeuille, Edouard Auclin, et al.
Oncotarget|October 15, 2017
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory <i>versus</i> locally advanced breast cancersAudrey Monneur, Anthony Goncalves, Marine Gilabert, et al.
Plos One|August 22, 2014
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparibMarine Gilabert, Simon Launay, Christophe Ginestier, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 13, 2019
International Study Group of Pancreatic Surgery type 3 and 4 venous resections in patients with pancreatic adenocarcinoma:the Paoli-Calmettes Institute experienceAbdallah Al Faraï, Jonathan Garnier, Jacques Ewald, et al.
World Journal of Surgical Oncology|June 6, 2019
Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinomaPauline Duconseil, Jonathan Garnier, Victoria Weets, et al.
Anti-Cancer Drugs|September 11, 2009
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 statusAnthony Gonçalves, Mathilde Deblock, Benjamin Esterni, et al.
BMC Medicine|September 21, 2017
A 25-gene classifier predicts overall survival in resectable pancreatic cancerDavid J Birnbaum, Pascal Finetti, Alexia Lopresti, et al.
JCI Insight|June 14, 2019
Sensitive and easy screening for circulating tumor cells by flow cytometryAlexia Lopresti, Fabrice Malergue, François Bertucci, et al.
Oncotarget|September 3, 2016
Prognostic value of PDL1 expression in pancreatic cancerDavid J Birnbaum, Pascal Finetti, Alexia Lopresti, et al.
Journal of Cellular Physiology|March 6, 2013
Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugsMarine Gilabert, Maria Inés Vaccaro, Martin E Fernandez-Zapico, et al.
British Journal of Cancer|January 30, 2022
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO studySonia Zaibet, Vincent Hautefeuille, Edouard Auclin, et al.
Oncotarget|October 15, 2017
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory <i>versus</i> locally advanced breast cancersAudrey Monneur, Anthony Goncalves, Marine Gilabert, et al.
Plos One|August 22, 2014
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparibMarine Gilabert, Simon Launay, Christophe Ginestier, et al.
Pageof 7